Jump Financial’s Cartesian Therapeutics RNAC Stock Holding History

Jump Financial’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,053	Closed	-$127K	–	2109
2023 Q1	$127K	Buy	+3,053	New	+$144K	0.01%	1401
2022 Q1	–	Sell	-1,420	Closed	-$139K	–	1857
2021 Q4	$139K	Buy	+1,420	New	+$153K	0.01%	1174
2021 Q1	–	Sell	-2,260	Closed	-$205K	–	1230
2020 Q4	$205K	Buy	2,260 +1,727	+324%	+$150K	0.03%	777
2020 Q3	$40K	Buy	+533	New	+$40.8K	0.01%	729

Other funds holding RNAC

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jump Financial's RNAC Position: Q2 2023 in Review

Jump Financial sold out of Cartesian Therapeutics (RNAC) in Q2 2023, closing a stake of 3,053 shares — an estimated $127K sold.

Jump Financial first reported a position in RNAC in Q3 2020 and held it in 4 quarters. The position peaked at $205K in Q4 2020. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2023.

Jump Financial reported no remaining Cartesian Therapeutics position as of Q2 2023 after selling out during the quarter.
Jump Financial sold 3,053 Cartesian Therapeutics shares in Q2 2023, an estimated $127K.
Jump Financial first reported a position in Cartesian Therapeutics in Q3 2020 and held it in 4 quarters.
Jump Financial's Cartesian Therapeutics position peaked at $205K in Q4 2020.
92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2023.

Based on Jump Financial's 13F filing for Q2 2023, filed 7 Aug 2023.